On July 29, 2026, the Nasdaq Hearings Panel granted Genprex an exception to maintain its listing on The Nasdaq Capital Market despite failing to meet the $1.00 Minimum Bid Price requirement. The company must demonstrate compliance by July 29, 2026, and maintain a closing bid price at or above $1.00 for each trading day until December 7, 2026. Genprex implemented a one-for-twenty-two (1:22) reverse stock split effective July 16, 2026, to address the deficiency. Failure to comply with these terms may result in delisting, which could negatively impact liquidity and capital access. Genprex is a clinical-stage biopharmaceutical company developing targeted therapies for cancer.
